Recent Finacing
Recent Raise
Granite Bio develops antibody therapeutics targeting inflammation and fibrosis; pipeline includes GRT‑001 (monocyte‑depleting, Phase 1a; Phase 1b IBD planned) and a preclinical IL‑3 blocker developed with Versant Ridgeline.
